Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2024 | IOB-032/PN-E40: pembrolizumab with a IO102-IO103 in melanoma and SCCHN

Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, gives an overview of the Phase II IOB-032/PN-E40 trial (NCT05280314), which evaluates IO102-IO103, a therapeutic cancer vaccine, plus pembrolizumab as neoadjuvant and adjuvant treatment in melanoma and squamous cell carcinoma of the head and neck (SCCHN). The primary endpoint is major pathological response at surgery, with secondary endpoints including safety, event-free survival, and disease-free survival. The trial includes multiple cohorts with planned crossover for poor responders, and aims to enhance treatment outcomes in resectable melanoma and SCCHN. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria – BMS; Pierre Fabre
Consulting or Advisory Role – Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.